| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 7780- | ISL, | Isoliquiritigenin alleviates LPS/ D-GalN-induced acute liver failure by activating the PGC-1α/ Nrf2 pathway to reduce oxidative stress and inflammatory response |
| - | in-vivo, | Nor, | NA |
| 7866- | isoO, | Orientin and Cancer Suppression: Molecular Mechanisms and Synergistic Effects |
| - | Review, | Var, | NA |
| 7865- | isoO, | Isoorientin inhibits oxidative stress to ameliorate cognitive dysfunction in type 2 diabetes mice via GSK3β/Nrf2 axis |
| - | in-vivo, | Diabetic, | NA |
| 7864- | isoO, | Isoorientin Inhibits Amyloid β25-35-Induced Neuronal Inflammation in BV2 Cells by Blocking the NF-κB Signaling Pathway |
| - | in-vitro, | AD, | BV2 |
| 7869- | isoO, | Apoptosis induction and inhibition of invasion and migration in gastric cancer cells by Isoorientin studied using network pharmacology |
| - | in-vitro, | GC, | HGC27 |
| 7854- | isoO, | Isoorientin induces apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cancer cells |
| - | in-vitro, | Liver, | HepG2 |
| 7855- | isoO, | Isoorientin induces apoptosis and autophagy simultaneously by reactive oxygen species (ROS)-related p53, PI3K/Akt, JNK, and p38 signaling pathways in HepG2 cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 7856- | isoO, | Isoorientin induces the apoptosis and cell cycle arrest of A549 human lung cancer cells via the ROS‑regulated MAPK, STAT3 and NF‑κB signaling pathways |
| - | in-vitro, | Lung, | A549 |
| 7885- | isoO, | Isoorientin from Gypsophila elegans induces apoptosis in liver cancer cells via mitochondrial-mediated pathway |
| 7880- | isoO, | Inhibition of ROS-mediated activation Src-MAPK/AKT signaling by orientin alleviates H2O2-induced apoptosis in PC12 cells |
| - | in-vitro, | Nor, | PC12 |
| - | vitro+vivo, | AD, | PC12 |
| 7816- | ISQ, | Isoquercitrin Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | HGC27 |
| 7798- | ISQ, | MOR, | Several targets involved in Alzheimer's disease amyloidogenesis are affected by morin and isoquercitrin |
| - | in-vitro, | AD, | NA |
| 7796- | ISQ, | Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway |
| - | vitro+vivo, | OS, | 143B | - | in-vitro, | OS, | U2OS |
| 7794- | ISQ, | Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 7848- | ISQ, | Review of anticancer mechanisms of isoquercitin |
| - | Review, | Var, | NA |
| 8011- | itraC, | Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | BC, | SkBr3 |
| 8012- | itraC, | Effects and mechanism of itraconazole on prostate cancer PC-3 cell apoptosis |
| - | in-vitro, | Pca, | PC3 |
| 2177- | itraC, | Itraconazole improves survival outcomes in patients with colon cancer by inducing autophagic cell death and inhibiting transketolase expression |
| - | Study, | Colon, | NA | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | HCT116 |
| 8039- | IVM, | Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy |
| - | NA, | neuroblastoma, | SH-SY5Y |
| 8034- | IVM, | doxoR, | Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation |
| - | in-vitro, | Oral, | NA |
| 8029- | IVM, | Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? |
| - | Review, | Var, | NA |
| 8028- | IVM, | Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential |
| - | Review, | Var, | NA |
| 8025- | IVM, | Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth |
| - | in-vitro, | CRC, | SW480 | - | in-vivo, | CRC, | HCT116 |
| 8024- | IVM, | Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | NE3 |
| 8045- | IVM, | Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway |
| - | in-vitro, | Cerv, | HeLa |
| 8043- | IVM, | Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE70 | - | in-vitro, | ESCC, | KYSE150 |
| 7896- | IVT, | VT, | Molecular targets of vitexin and isovitexin in cancer therapy: a critical review |
| - | Review, | Var, | NA |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 7893- | IVT, | Isovitexin (IV) induces apoptosis and autophagy in liver cancer cells through endoplasmic reticulum stress |
| - | vitro+vivo, | Liver, | NA |
| 8008- | JG, | Juglone, isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of AR expression in human prostate cancer LNCaP cells |
| - | in-vitro, | NA, | LNCaP |
| 8007- | JG, | Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis |
| - | in-vitro, | GBM, | U251 |
| 7965- | JG, | Mechanistic investigation of Juglone (5-hydroxy-1,4-naphthoquinone) as an anti-cancer agent in human colorectal cancer HCT116 and HT-29 cell lines |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 5113- | JG, | Juglone in Oxidative Stress and Cell Signaling |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5114- | JG, | Juglone, from Juglans mandshruica Maxim, inhibits growth and induces apoptosis in human leukemia cell HL-60 through a reactive oxygen species-dependent mechanism |
| - | in-vitro, | AML, | HL-60 |
| 5115- | JG, | Natural Products to Fight Cancer: A Focus on Juglans regia |
| - | Review, | Var, | NA |
| 1918- | JG, | ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | NA, | NA |
| 1927- | JG, | Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway |
| - | in-vitro, | GC, | SGC-7901 |
| 1926- | JG, | Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway |
| - | in-vitro, | BC, | MCF7 |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 8090- | KAE, | A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound |
| - | Review, | Nor, | NA |
| 8095- | KAE, | Kaempferol: A Key Emphasis to Its Anticancer Potential |
| - | Review, | Var, | NA |
| 8097- | KAE, | The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells |
| - | in-vitro, | CRC, | LS174T |
| 8102- | KAE, | Kaempferol inhibits gastric cancer tumor growth: An in vitro and in vivo study |
| - | vitro+vivo, | GC, | MKN-28 | - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | GC, | GES-1 |
| 8105- | KAE, | Chemo-preventive and therapeutic effect of the dietary flavonoid kaempferol: A comprehensive review |
| - | Review, | Var, | NA |
| 8060- | KAE, | Mechanisms underlying apoptosis-inducing effects of Kaempferol in HT-29 human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 8061- | KAE, | Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | OVCAR-3 |
| 8063- | KAE, | Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways |
| - | in-vitro, | Ovarian, | NA |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| 8075- | KAE, | QC, | Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid